Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKE-154
- Development stage
- Preclinical
- Lead developer
- CHA University
- Modality
- Small Molecules
01
Overview
SKE-154 (also known as SKE154) is a novel, non-cytotoxic small molecule agonist of estrogen-related receptor gamma (ERRγ). Developed by researchers at CHA University and Kyungsung University, SKE-154 acts as a potent activator of ERRγ, promoting adult neurogenesis in the hippocampal subgranular zone (SGZ) and enhancing the maturation and functional integration of newborn neurons. It upregulates brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB)/cAMP-response element binding protein (CREB) signaling, and modulates the serotonergic system by upregulating markers such as EGR1, TPH2, SERT, and 5-HT Rc1A. SKE-154 is being investigated as a potential therapeutic candidate for neurodegenerative and neuropsychiatric disorders.
02
Targets
ESRRG (Estrogen-related receptor gamma)
Beyond the preview
Go deeper on SKE-154.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKE-154.